- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01424878
Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
Study of Molecular Pathways in Medullary Thyroid Carcinoma (MTC) and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
Background:
Medullary thyroid carcinoma (MTC) is a rare malignancy, occurring either as a sporadic disease (75% of cases), or in a hereditary pattern as multiple endocrine neoplasia (MEN) type 2 (MEN2A or MEN2B) or familial medullary thyroid carcinoma (FMTC). The MTC arises from the neural crest C-cells and in hereditary cases the first pathological disorder is C-cell hyperplasia (CCH) Most patients with MTC have advanced disease at the time of diagnosis.
Chemotherapy and external beam radiotherapy have been minimally effective. Molecular targeted therapeutics (MTTs) and other receptor kinases in patients with advanced MTC have demonstrated activity.
Despite some clinical responses, the collection of tumor tissues and autologous normal tissues has been virtually non-existent. Thus, laboratory studies defining affected molecular targets and downstream pathways, and molecular data providing direction for future clinical trials has yet to occur.
Data from molecular studies of tumor tissue of hereditary or sporadic MTC patients will assist in predicting clinical behavior and the biology of MTC in predicting response to a given MTT, and in designing combination clinical trials.
Objectives:
Clarify how normal molecular pathways are altered by mutations in the RET protooncogene. Including additional genetic mutations and unidentified chromosomal translocations.
Correlate results from molecular analyses of MTC tissue with patient s clinical course.
Define how the molecular and clinical data will be useful in designing targeted therapy for patients with MTC.
Eligibility:
Patients must have confirmed diagnosis of C-cell hyperplasia, primary MTC, or metastatic MTC with archived pathology specimens available at Washington University.
Design:
Paraffin blocks of MTC tissues from archival samples at Washington University Department of Pathology will be selected.
H&E slide from selected tissue blocks will be examined for molecular study suitability.
Necessary tissue samples from blocks will have molecular studies, including, gene arrays, array comparative genomic hybridization, immunohistochemistry, and sequencing.
Retrospective chart review will occur to obtain relevant clinical information.
Study Overview
Status
Detailed Description
Background:
Medullary thyroid carcinoma (MTC) is a rare malignancy, occurring either as a sporadic disease (75% of cases), or in a hereditary pattern as multiple endocrine neoplasia (MEN) type 2 (MEN2A or MEN2B) or familial medullary thyroid carcinoma (FMTC). The MTC arises from the neural crest C-cells and in hereditary cases the first pathological disorder is C-cell hyperplasia (CCH) Most patients with MTC have advanced disease at the time of diagnosis.
Chemotherapy and external beam radiotherapy have been minimally effective. Molecular targeted therapeutics (MTTs) and other receptor kinases in patients with advanced MTC have demonstrated activity.
Despite some clinical responses, the collection of tumor tissues and autologous normal tissues has been virtually non-existent. Thus, laboratory studies defining affected molecular targets and downstream pathways, and molecular data providing direction for future clinical trials has yet to occur.
Data from molecular studies of tumor tissue of hereditary or sporadic MTC patients will assist in predicting clinical behavior and the biology of MTC in predicting response to a given MTT, and in designing combination clinical trials.
Objectives:
Clarify how normal molecular pathways are altered by mutations in the RET protooncogene. Including additional genetic mutations and unidentified chromosomal translocations.
Correlate results from molecular analyses of MTC tissue with patient s clinical course.
Define how the molecular and clinical data will be useful in designing targeted therapy for patients with MTC.
Eligibility:
Patients must have confirmed diagnosis of C-cell hyperplasia, primary MTC, or metastatic MTC with archived pathology specimens available at Washington University.
Design:
Paraffin blocks of MTC tissues from archival samples at Washington University Department of Pathology will be selected.
H&E slide from selected tissue blocks will be examined for molecular study suitability.
Necessary tissue samples from blocks will have molecular studies, including, gene arrays, array comparative genomic hybridization, immunohistochemistry, and sequencing.
Retrospective chart review will occur to obtain relevant clinical information.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Cancer Institute (NCI), 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA:
Patients must have confirmed diagnosis of C-cell hyperplasia, primary MTC, or metastatic MTC with archived pathology specimens available at Washington University.
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Antonio T Fojo, M.D.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Genetic Diseases, Inborn
- Head and Neck Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neoplastic Syndromes, Hereditary
- Neuroendocrine Tumors
- Neoplasms, Multiple Primary
- Carcinoma
- Thyroid Diseases
- Thyroid Neoplasms
- Carcinoma, Neuroendocrine
- Endocrine Gland Neoplasms
- Multiple Endocrine Neoplasia
- Multiple Endocrine Neoplasia Type 2a
Other Study ID Numbers
- 999910167
- 10-C-N167
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Endocrine Neoplasia Type 2
-
National Cancer Institute (NCI)CompletedMultiple Endocrine Neoplasia Type 2A | Multiple Endocrine Neoplasia Type 2B | Medullary Thyroid CarcinomaUnited States
-
Centre Hospitalier Universitaire DijonRecruitingMultiple Endocrine NeoplasiaFrance
-
Centre Hospitalier Universitaire DijonUnknownType 1-Multiple Endocrine Neoplasia SyndromeFrance
-
Centre Hospitalier Universitaire DijonRecruiting
-
National Cancer Institute (NCI)CompletedMultiple Endocrine Neoplasia Type 2A | Multiple Endocrine Neoplasia Type 2B | Recurrent Thyroid Gland Medullary Carcinoma | Hereditary Thyroid Gland Medullary Carcinoma | Locally Advanced Thyroid Gland Medullary Carcinoma | Sporadic Thyroid Gland Medullary Carcinoma | Stage III Thyroid Gland Medullary... and other conditionsUnited States
-
National University Health System, SingaporeCompletedThymic Carcinoid | Multiple Endocrine Neoplasia Type 1 (MEN-1)Singapore
-
University Hospital, Basel, SwitzerlandRecruiting
-
M.D. Anderson Cancer CenterActive, not recruitingMultiple Endocrine Neoplasia SyndromesUnited States
-
National Institute of Diabetes and Digestive and...RecruitingPrimary Hyperparathyroidism | Pseudohypoparathyroidism | Parathyroid Cancer | Inheritable Bone Diseases | Multiple Endocrine Neoplasia, Type 1United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingNeuroendocrine Neoplasm | Multiple Endocrine Neoplasia Type 1 | Advanced Carcinoid Tumor | Digestive System Neuroendocrine Neoplasm | Unresectable Carcinoid TumorUnited States